Production (Stage)
aTyr Pharma, Inc.
ATYR
$3.75
-$0.05-1.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -11.60% | -4.13% | 43.49% | 42.00% | 42.49% |
| Gross Profit | 10.02% | 4.13% | -48.58% | -42.00% | -39.98% |
| SG&A Expenses | 12.89% | 12.11% | 25.93% | -10.11% | 2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.51% | -0.87% | 39.91% | 27.71% | 31.94% |
| Operating Income | 5.19% | 0.87% | -43.82% | -27.71% | -30.10% |
| Income Before Tax | 3.91% | -1.40% | -52.19% | -32.12% | -29.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.91% | -1.40% | -52.19% | -32.12% | -29.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 125.00% | 0.00% | 0.00% | -- | -500.00% |
| Net Income | 3.94% | -1.40% | -52.20% | -32.16% | -29.62% |
| EBIT | 5.19% | 0.87% | -43.82% | -27.71% | -30.10% |
| EBITDA | 5.18% | 0.88% | -44.42% | -27.92% | -29.52% |
| EPS Basic | 26.58% | 27.38% | -16.23% | -0.85% | 17.81% |
| Normalized Basic EPS | 26.62% | 27.36% | -16.26% | -0.86% | 17.84% |
| EPS Diluted | 26.58% | 27.38% | -16.23% | -0.85% | 17.81% |
| Normalized Diluted EPS | 26.62% | 27.36% | -16.26% | -0.86% | 17.84% |
| Average Basic Shares Outstanding | 30.88% | 39.59% | 30.95% | 31.08% | 57.72% |
| Average Diluted Shares Outstanding | 30.88% | 39.59% | 30.95% | 31.08% | 57.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |